Grant: Engage Plus Grants Program
University of Victoria
$12,390.00
Analysis of enzymes to use for the modification of fucoidan.
FY 2015-16
Summary
Fucoidan is a polysaccharide found in brown algae (seaweed). ARC Medical Devices Inc. has developed and
markets fucoidan extracted and purified from brown algae for post-surgical veterinary use to reduce adhesion
development. This works very effectively, prompting a desire to develop the product for use in humans. The
challenge to this, however, is that fucoidan is an extremely large molecule of heterogeneous composition,
making it difficult to a) meet the higher standards of purity and homogeneity required of medical materials for
use in human subjects and b) do so in quantities required for human trials.
Our proposed solution is to harness naturally occurring enzymes found in marine bacteria and use these
bio-processing enzymes to tailor the structure and size of fucoidan, and/or synthesize fucoidan fragments, such
that the material is of more defined size and composition and can ultimately be obtained in large quantities of
high purity. The pathway envisioned to achieve this has multiple steps, with the particular objective of this
proposal being to achieve the initial and critical steps of generating the enzymatic tools required to enable the
remodeling and/or synthesis of fucoidan.
Successful completion of the project will result in a process to produce a novel, first in class medical device
for the reduction of post-surgical adhesions in humans, which in turn will reduce pain, suffering, infertility and
mortality in Canadian patients following common surgical procedures; reduce Canadian hospital stays, hospital
re-admissions, and re-operations, which in turn will reduce healthcare costs for Canadian governments and
taxpayers; and create scientific, manufacturing and sales jobs within Canada.
Program
Engage Plus Grants Program
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
491210-2015
Name nom
Boraston, Alisdair
Department département
Biochemistry and Microbiology
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
12390
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Partie
1
Nb partie
1
Application title
Analysis of enzymes to use for the modification of fucoidan.
Keyword
NSERC
Application summary
Fucoidan is a polysaccharide found in brown algae (seaweed). ARC Medical Devices Inc. has developed and
markets fucoidan extracted and purified from brown algae for post-surgical veterinary use to reduce adhesion
development. This works very effectively, prompting a desire to develop the product for use in humans. The
challenge to this, however, is that fucoidan is an extremely large molecule of heterogeneous composition,
making it difficult to a) meet the higher standards of purity and homogeneity required of medical materials for
use in human subjects and b) do so in quantities required for human trials.
Our proposed solution is to harness naturally occurring enzymes found in marine bacteria and use these
bio-processing enzymes to tailor the structure and size of fucoidan, and/or synthesize fucoidan fragments, such
that the material is of more defined size and composition and can ultimately be obtained in large quantities of
high purity. The pathway envisioned to achieve this has multiple steps, with the particular objective of this
proposal being to achieve the initial and critical steps of generating the enzymatic tools required to enable the
remodeling and/or synthesis of fucoidan.
Successful completion of the project will result in a process to produce a novel, first in class medical device
for the reduction of post-surgical adhesions in humans, which in turn will reduce pain, suffering, infertility and
mortality in Canadian patients following common surgical procedures; reduce Canadian hospital stays, hospital
re-admissions, and re-operations, which in turn will reduce healthcare costs for Canadian governments and
taxpayers; and create scientific, manufacturing and sales jobs within Canada.